Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.
Jakob Schöllhammer KnudsenLisbeth M BaggesenMaria LajerLarisa NurkanovicAnastasia UstyugovaHenrik T SørensenReimar Wernich ThomsenPublished in: PloS one (2020)
Following the EMPA-REG OUTCOME trial in 2015, SGLT2i have become increasingly used as 2nd-line treatment in everyday clinical practice, with only minor increases in patient proportions with ASCVD. For GLP-1RA, we observed more stable therapy lines and slightly decreasing ASCVD in new users despite the LEADER trial.